PMV Pharmaceuticals Inc
NASDAQ:PMVP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
PMV Pharmaceuticals Inc
NASDAQ:PMVP
|
US |
|
Cogent Biosciences Inc
NASDAQ:COGT
|
US |
|
G-III Apparel Group Ltd
NASDAQ:GIII
|
US |
|
O
|
Ostim Endustriyel Yatirimlar ve Isletme AS
IST:OSTIM.E
|
TR |
|
Siyaram Silk Mills Ltd
NSE:SIYSIL
|
IN |
Balance Sheet
Balance Sheet Decomposition
PMV Pharmaceuticals Inc
PMV Pharmaceuticals Inc
Balance Sheet
PMV Pharmaceuticals Inc
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
30
|
73
|
361
|
173
|
108
|
38
|
41
|
38
|
|
| Cash Equivalents |
30
|
73
|
361
|
173
|
108
|
38
|
41
|
38
|
|
| Short-Term Investments |
32
|
28
|
0
|
125
|
133
|
165
|
129
|
75
|
|
| Other Current Assets |
0
|
1
|
3
|
4
|
6
|
4
|
6
|
2
|
|
| Total Current Assets |
62
|
102
|
365
|
301
|
247
|
207
|
176
|
115
|
|
| PP&E Net |
1
|
1
|
1
|
13
|
21
|
19
|
2
|
1
|
|
| PP&E Gross |
1
|
1
|
1
|
13
|
21
|
19
|
2
|
1
|
|
| Accumulated Depreciation |
1
|
1
|
2
|
2
|
2
|
3
|
1
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
17
|
3
|
26
|
14
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
64
N/A
|
103
+62%
|
366
+255%
|
332
-9%
|
270
-18%
|
252
-7%
|
191
-24%
|
117
-39%
|
|
| Liabilities | |||||||||
| Accounts Payable |
1
|
3
|
2
|
3
|
3
|
3
|
7
|
3
|
|
| Accrued Liabilities |
1
|
2
|
5
|
9
|
8
|
11
|
8
|
8
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
5
|
6
|
12
|
11
|
14
|
14
|
11
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
11
|
13
|
12
|
1
|
0
|
|
| Total Liabilities |
2
N/A
|
5
+92%
|
6
+39%
|
23
+259%
|
24
+6%
|
26
+9%
|
15
-43%
|
12
-22%
|
|
| Equity | |||||||||
| Common Stock |
107
|
169
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
50
|
75
|
110
|
168
|
241
|
310
|
369
|
446
|
|
| Additional Paid In Capital |
4
|
5
|
469
|
476
|
488
|
535
|
545
|
551
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
61
N/A
|
99
+61%
|
359
+265%
|
309
-14%
|
246
-20%
|
226
-8%
|
176
-22%
|
105
-41%
|
|
| Total Liabilities & Equity |
64
N/A
|
103
+62%
|
366
+255%
|
332
-9%
|
270
-18%
|
252
-7%
|
191
-24%
|
117
-39%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
43
|
43
|
45
|
45
|
46
|
51
|
52
|
53
|
|